IHH Healthcare has announced impressive financial results for the second quarter of 2024, showcasing significant double-digit growth across key metrics. The group's revenue surged by 30% to RM6.1 billion, while EBITDA rose 34% to RM1.4 billion. Profit After Tax and Minority Interests (PATMI), excluding exceptional items, increased by 39% to RM437 million. PATMI, including all items, more than doubled to RM623 million.
For the first half of 2024, IHH Healthcare continued its strong performance with a 23% rise in revenue to RM12.0 billion and a 26% increase in EBITDA to RM2.7 billion. PATMI, excluding exceptional items, grew by 30% to RM840 million. However, PATMI, including all items, fell by 18% due to a high base last year, which benefited from RM862 million in one-off gains from the sale of International Medical University (IMU).
Dr Prem Kumar Nair, Group Chief Executive Officer of IHH Healthcare, commented, "We have delivered an outstanding performance in the first half of 2024, marked by two consecutive quarters of record revenue and strong operational excellence. Our focus on providing quality patient care and excellent outcomes remains paramount. Our recent initiatives, including the launch of IHH Singapore's first transitional care facility and Fortis Memorial Research Institute's new Gamma Knife Esprit treatment, further solidify our position as a leader in healthcare."
The group's operational summary for Q2 2024 highlights sustained growth, with revenue and EBITDA reflecting strong patient volume and complex case management across all markets. PATMI more than doubled, driven by strong operational performance, deferred tax credits, and net monetary gains from applying MFRS 129. Excluding exceptional items, PATMI (ex EI) saw a 39% increase.
IHH Healthcare has recently made strategic appointments to its Board of Directors, including Tan Sri Dr Nik Norzrul Thani Nik Hassan Thani as Chairman and Independent Non-Executive Director, and Chua Bin Hwee as Audit Committee Chairman and Independent Non-Executive Director. Additionally, the group has expanded its facilities and capabilities, such as breaking ground on TCF@East, IHH Singapore's first transitional care facility, and introducing Gamma Knife Esprit at Fortis Memorial Research Institute.
IHH医疗集团宣布了2024年第二季度的骄人财报，在各项关键指标上都取得了两位数的显著增长。该集团的收入激增 30%，达到 61 亿令吉，息税折旧摊销前利润（EBITDA）增长 34%，达到 14 亿令吉。不包括特殊项目的税后和少数股东权益（PATMI）增长了39%，达到4.37亿令吉。包括所有项目在内的税后及少数股东权益（PATMI）增长了一倍多，达到 6.23 亿令吉。
2024 年上半年，IHH 医疗保健继续保持强劲表现，营收增长 23% 至 120 亿令吉，息税折旧摊销前利润（EBITDA）增长 26% 至 27 亿令吉。不包括特殊项目的PATMI增长了30%，达到8.4亿令吉。然而，包括所有项目在内的PATMI则下跌18%，原因是去年的基数较高，受惠于出售国际医科大学（IMU）的8亿6千2百万令吉一次性收益。
IHH医疗集团首席执行官Prem Kumar Nair博士评论道："我们在2024年上半年取得了出色的业绩表现，连续两个季度创下创纪录的收入和卓越的运营表现。我们始终专注于提供优质的患者护理和卓越的疗效。我们最近推出的举措，包括 IHH 新加坡首家过渡性护理设施的启动和富通纪念研究所的新型伽玛刀 Esprit 治疗，进一步巩固了我们在医疗保健领域的领先地位。
集团 2024 年第二季度的运营总结显示了持续的增长，收入和息税折旧摊销前利润（EBITDA）反映了所有市场强劲的患者数量和复杂的病例管理。在强劲的运营业绩、递延税款抵免和应用 MFRS 129 带来的净货币收益的推动下，PATMI 增长了一倍多。剔除特殊项目后，PATMI（不包括 EI）增长了 39%。
IHH Healthcare 最近对董事会进行了战略性任命，包括任命 Tan Sri Dr Nik Norzrul Thani Nik Hassan Thani 为主席兼独立非执行董事，任命 Chua Bin Hwee 为审计委员会主席兼独立非执行董事。此外，集团还扩大了其设施和能力，如 IHH 新加坡首个过渡性护理设施 TCF@East 破土动工，并在富通纪念研究所引进了伽玛刀 Esprit。
